M
Magnus Björkholm
Researcher at Karolinska University Hospital
Publications - 475
Citations - 18743
Magnus Björkholm is an academic researcher from Karolinska University Hospital. The author has contributed to research in topics: Population & Telomerase reverse transcriptase. The author has an hindex of 68, co-authored 468 publications receiving 16987 citations. Previous affiliations of Magnus Björkholm include Karolinska Institutet & Lund University.
Papers
More filters
Journal ArticleDOI
Acute myeloid leukaemia.
Asim Khwaja,Magnus Björkholm,Rosemary E. Gale,Ross L. Levine,Craig T. Jordan,Gerhard Ehninger,Clara D. Bloomfield,Eli Estey,Alan Kenneth Burnett,Jan J. Cornelissen,David A. Scheinberg,Didier Bouscary,David C. Linch +12 more
TL;DR: A plethora of new agents — including those targeted at specific biochemical pathways and immunotherapeutic approaches — are now in trial based on improved understanding of disease pathophysiology, providing good grounds for optimism, although mortality remains high especially in older patients.
Journal ArticleDOI
Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population
Hannah Bower,Magnus Björkholm,Paul W. Dickman,Martin Höglund,Paul C. Lambert,Therese M.-L. Andersson +5 more
TL;DR: Imatinib mesylate and new TKIs along with allogeneic stem cell transplantation and other factors have contributed to the life expectancy in patients with CML approaching that of the general population today.
Journal ArticleDOI
Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL).
Jeanette Lundin,Eva Kimby,Magnus Björkholm,Per-Anders Broliden,Fredrik Celsing,Viktoria Hjalmar,Lars Möllgård,Peppy Rebello,Geoff Hale,Herman Waldmann,Håkan Mellstedt,Anders Österborg +11 more
TL;DR: Subcutaneous administration of alemtuzumab as first-line treatment in patients with symptomatic B-cell chronic lymphocytic leukemia induced very few "first-dose" flulike symptoms and may reduce health care costs in comparison with the intravenous infusions.
Journal ArticleDOI
Switch from Myc/Max to Mad1/Max binding and decrease in histone acetylation at the telomerase reverse transcriptase promoter during differentiation of HL60 cells.
Dawei Xu,Nikita Popov,Mi Hou,Qian Wang,Magnus Björkholm,Astrid Gruber,Annette R. Menkel,Marie Henriksson +7 more
TL;DR: The in vivo interaction between endogenous c-Myc and Mad1 proteins and the hTERT promoter in HL60 cells with the use of the chromatin immunoprecipitation assay indicates that acetylation/deacetylation of histones is operative in the regulation of h TERT expression.
Journal ArticleDOI
Patterns of Survival in Multiple Myeloma: A Population-Based Study of Patients Diagnosed in Sweden From 1973 to 2003
TL;DR: High-dose melphalan with subsequent autologous stem-cell transplantation, thalidomide, and a continuous improvement in supportive care measures are probably the most important factors contributing to this finding of increased one-year multiple myeloma survival.